204 related articles for article (PubMed ID: 30051919)
1. Increase in antinuclear antibody levels through biologic treatment for psoriasis.
Miki M; Endo C; Naka Y; Fukuya Y; Kobayashi S; Kawashima M; Tsunemi Y
J Dermatol; 2019 Feb; 46(2):e50-e51. PubMed ID: 30051919
[No Abstract] [Full Text] [Related]
2. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.
Yanaba K; Umezawa Y; Honda H; Sato R; Chiba M; Kikuchi S; Asahina A; Nakagawa H
J Dermatol; 2016 Apr; 43(4):443-4. PubMed ID: 26662275
[No Abstract] [Full Text] [Related]
3. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
4. Efficacies of biological therapies at week 12 in patients with plaque psoriasis in real-world academic clinical practice: a Canadian multicentre retrospective study.
Shahbaz A; Qiang J; Marinas JEC; Kim WB; Greaves S; Yeung J
Br J Dermatol; 2017 Jul; 177(1):297-298. PubMed ID: 27639251
[No Abstract] [Full Text] [Related]
5. Switching biologics in severe pediatric psoriasis: a retrospective analysis.
Ramos Pinheiro R; Diamantino F; Cabete J; Brasileiro A; Baptista J; Lopes MJP
Int J Dermatol; 2017 Dec; 56(12):1461-1464. PubMed ID: 28960270
[No Abstract] [Full Text] [Related]
6. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Menter A; Strober BE; Kaplan DH; Kivelevitch D; Prater EF; Stoff B; Armstrong AW; Connor C; Cordoro KM; Davis DMR; Elewski BE; Gelfand JM; Gordon KB; Gottlieb AB; Kavanaugh A; Kiselica M; Korman NJ; Kroshinsky D; Lebwohl M; Leonardi CL; Lichten J; Lim HW; Mehta NN; Paller AS; Parra SL; Pathy AL; Rupani RN; Siegel M; Wong EB; Wu JJ; Hariharan V; Elmets CA
J Am Acad Dermatol; 2019 Apr; 80(4):1029-1072. PubMed ID: 30772098
[TBL] [Abstract][Full Text] [Related]
7. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study.
Marinas JE; Kim WB; Shahbaz A; Qiang JK; Greaves S; Yeung J
Australas J Dermatol; 2018 Feb; 59(1):e11-e14. PubMed ID: 27858976
[TBL] [Abstract][Full Text] [Related]
8. Long persistence of tumour necrosis factor-α antagonist-induced autoantibodies under subsequent treatment with ustekinumab but no adverse effects: a case study of 14 patients with psoriasis.
Hoffmann JHO; Knoop C; Enk AH; Hadaschik EN
Br J Dermatol; 2018 Jan; 178(1):e9-e10. PubMed ID: 28581119
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
Qiang JK; Shahbaz A; Kim W; Marinas J; Greaves S; Yeung J
J Am Acad Dermatol; 2016 Jan; 74(1):176-7. PubMed ID: 26702799
[No Abstract] [Full Text] [Related]
11. Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life.
Puig L; Morales-Múnera CE
Eur J Dermatol; 2013; 23(3):407-8. PubMed ID: 23782978
[No Abstract] [Full Text] [Related]
12. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
13. Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users.
Ighani A; Yu AM; Sandhu VK; Barankin B; Manolson MF
J Cutan Med Surg; 2019; 23(2):148-156. PubMed ID: 30801221
[TBL] [Abstract][Full Text] [Related]
14. A retrospective observational study on biological drug treatment in a daily practice serving patients with psoriasis in Japan.
Ohata C; Ohyama B; Nanri A; Shintani T; Nakama T
J Dermatolog Treat; 2019 Feb; 30(1):45-48. PubMed ID: 29676591
[TBL] [Abstract][Full Text] [Related]
15. Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination.
Haberman RH; Castillo R; Scher JU
Rheumatology (Oxford); 2021 Jul; 60(7):e225-e226. PubMed ID: 33369644
[No Abstract] [Full Text] [Related]
16. Switching of biologics in psoriasis: Reasons and results.
Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
[TBL] [Abstract][Full Text] [Related]
17. Evolving Landscape of Biologic Therapy for Pediatric Psoriasis.
Do H; Babbush Graber K; Chernoff KA; Melnick LE
Dermatol Clin; 2024 Jul; 42(3):377-386. PubMed ID: 38796269
[TBL] [Abstract][Full Text] [Related]
18. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review.
Bartos G; Cline A; Beroukhim K; Burrall BA; Feldman SR
Dermatol Online J; 2018 Nov; 24(11):. PubMed ID: 30695971
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
Asahina A; Kubo N; Umezawa Y; Honda H; Yanaba K; Nakagawa H
J Dermatol; 2017 Oct; 44(10):1112-1121. PubMed ID: 28493493
[TBL] [Abstract][Full Text] [Related]
20. Elderly psoriatic patients under biological therapies: an Italian experience.
Ricceri F; Bardazzi F; Chiricozzi A; Dapavo P; Ferrara F; Mugheddu C; Romanelli M; Rongioletti F; Prignano F
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):143-146. PubMed ID: 29906311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]